Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eczema pill shows early promise in small trial

NCT ID NCT07336940

First seen Jan 14, 2026 · Last updated May 25, 2026 · Updated 16 times

Summary

This early-stage study tested a new drug called ENV-294 in 9 adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to check if the drug is safe and tolerable when taken daily for 28 days. Researchers also looked for any changes in skin symptoms. This is a small, first-in-human trial, so results are preliminary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California, 94538, United States

  • J & S Studies

    College Station, Texas, 77845, United States

  • Skin Sciences, PLLC

    Louisville, Kentucky, 40217, United States

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas, 78218, United States

  • Virginia Dermatology & Skin Cancer Center

    Norfolk, Virginia, 23502, United States

Conditions

Explore the condition pages connected to this study.